Physician profile
Brian E Lee
NPI 1881768596
$2,393.92
in general payments reported to CMS, 2019-2025
32 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $415 · 2021: $494 · 2022: $170 · 2023: $276 · 2024: $331 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $419.52 | 2021-2024 | |
| Pfizer INC. | $315.30 | 2019-2022 | |
| Novo Nordisk INC | $251.90 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $154.59 | 2019-2025 | Farxiga, Airsupra |
| Mannkind Corporation | $126.36 | 2019-2020 | |
| Dexcom, INC. | $99.74 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $93.63 | 2021-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $88.60 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.35 | 2022-2025 | |
| Abbott Laboratories | $78.72 | 2021-2025 | Freestyle Libre 3 |
| Orexo US, INC. | $65.14 | 2023-2025 | Zubsolv |
| Takeda Pharmaceuticals U.S.A., INC. | $56.28 | 2019-2020 | |
| Eisai INC. | $52.45 | 2020-2021 | |
| Medtronic, INC. | $43.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $42.89 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $41.00 | 2019 | |
| Merck Sharp & Dohme LLC | $39.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.94 | 2019 | |
| Allergan, INC. | $35.81 | 2020 | |
| Mylan Specialty L.P. | $34.99 | 2021 | |
| Glaxosmithkline, LLC. | $31.78 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Forte Bio-Pharma LLC | $30.53 | 2025 | Prolate, Nalocet, Tanlor |
| Averitas Pharma INC. | $26.42 | 2025 | Qutenza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.48 | 2022 | |
| Cardiovascular Systems INC. | $20.30 | 2020 | |
| Csl Behring | $17.77 | 2024 | Haegarda |
| Vertical Pharmaceuticals, LLC | $16.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.63 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.44 | 2022 | |
| Astellas Pharma US INC | $12.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.73 | 2020 | |
| Amarin Pharma, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.